The buyback provides a tangible floor under the stock and signals management's view that shares are undervalued. Monitor weekly buyback execution updates on the company's IR page; consistent repurchases at current levels would be a positive signal. The program runs through May 2027, so the impact will be gradual.
Price Chart
Executive Summary
Fresenius Medical Care launched the first tranche of a new EUR 1 billion share buyback program, with up to EUR 600 million to be repurchased by December 15, 2026. Shares repurchased will predominantly be cancelled, reducing share capital. The program signals management's confidence in cash generation and commitment to shareholder returns, but no financial results or guidance were provided in this filing.
Key Facts
- Total buyback program volume of up to EUR 1 billion (approx. USD 1.09 billion at current rates).
- First tranche of up to EUR 600 million launched May 28, 2026, expected completion by December 15, 2026.
- Up to 29,341,344 shares may be repurchased under the program.
- Repurchased shares will predominantly be cancelled, reducing share capital.
- Program authorized by Annual General Meeting on May 21, 2026.
- A credit institution has been mandated to execute purchases independently.
Financial Impact
EUR 1 billion total buyback (first tranche EUR 600 million). Represents approximately 4.5% of market cap based on typical valuation metrics.
Risk Factors
- Buyback execution depends on free cash flow generation; any operational deterioration could slow or halt repurchases.
- No financial results or guidance were provided in this filing — the buyback alone does not address underlying business trends.
- The program is subject to volume and price constraints (max 25% of daily turnover, price limits relative to Xetra opening auction).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-067280 |
| Document: tm2615883d1_ex99-2.htm | 0001104659-26-067280 |
| Document: tm2615883d1_ex99-1.htm | 0001104659-26-067280 |
| Document: 0001104659-26-067280-index-headers.html | 0001104659-26-067280 |
| Document: 0001104659-26-067280-index.html | 0001104659-26-067280 |
| Document: 0001104659-26-067280.txt | 0001104659-26-067280 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 28, 2026 21w ago | 6-K | $42.00 $51.44 | ▲ +22.48% | ▲ +20.74% | $43.82 (+4.33%) |
May 26, 2026 22w ago | 6-K | $42.00 $51.44 | ▲ +22.48% | ▲ +19.75% | $43.82 (+4.33%) |
May 5, 2026 25w ago | 6-K | $43.08 $49.82 | ▼ −15.65% | ▼ −12.91% | $43.82 (−1.72%) |
Apr 14, 2026 28w ago | 6-K | $44.25 $44.59 | ▲ +0.77% | ▼ −7.75% | $43.82 (−0.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers